Two ratings put Organogenesis stock at a USD 2.00 average target

Published on 10/20/2026 at 21:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Organogenesis stock is down 80.41 percent year to date on October 20, 2026. It costs EUR 0.92 on October 20, 2026 at 9:41 p.m. CEST.

Targets and operating figures

An average target of USD 2.00 came from two ratings on October 20, 2026.
Second-quarter 2026 revenue was USD 43.80 million, down 56.68 percent year over year.
The Lang & Schwarz quote was EUR 0.92 on October 20, 2026 at 9:41 p.m. CEST.

ORGO, US68621F1021, Illustration mit AI erstellt.

Organogenesis Holdings (ISIN US68621F1021) has an average USD 2.00 price target based on two ratings, as Barron's reported on October 20, 2026. The target is 94.17 percent above the Nasdaq price of USD 1.03 at 3:47 p.m. EDT. At Lang & Schwarz, the stock was trading at EUR 0.92 on October 20, 2026 at 9:41 p.m. CEST in after-hours trading.

Revenue remains the key measure

Organogenesis reported USD 43.80 million in revenue for the second quarter of 2026, down 56.68 percent from the same period a year earlier, according to Quiver Quantitative. The comparison places the USD 2.00 target against a business that is still working through a sharp decline in reported sales.

Stock sits near its yearly low

On the Nasdaq, Organogenesis was last at USD 1.03 on October 20, 2026 at 3:47 p.m. EDT. The session range was USD 1.00 to USD 1.04, while the 52-week range was USD 0.93 to USD 7.08. The Nasdaq price was 10.75 percent above the yearly low and 85.45 percent below the yearly high. Barron's listed year-to-date performance at minus 80.41 percent.

What dates matter next?

GlobeNewswire reported on October 12, 2026 that Organogenesis will publish third-quarter fiscal 2026 results after the market closes on November 5, 2026. Management scheduled its conference call for 5:00 p.m. Eastern Time the same day.

Peer valuations show a wide spread

Comparison with peers

Organogenesis: down 80.41 percent year to date, market capitalization USD 131.3 million, 52-week range USD 0.93 to USD 7.08.

Amneal Pharmaceuticals (Nasdaq, USD): up 2.44 percent on October 20, 2026, P/E 40.68, market capitalization USD 6.3 billion.

Eagle Pharmaceuticals (Nasdaq, USD): down 14.77 percent on October 16, 2026, P/E 0.27, market capitalization USD 9.9 million.

Target and operating risk

The USD 2.00 average target is a substantial distance above the latest Nasdaq quote, while the second-quarter revenue decline highlights the operating challenge behind that valuation gap. The scheduled November report is the next dated test for revenue recovery and execution.

The stock was trading at EUR 0.92 at Lang & Schwarz on October 20, 2026 at 9:41 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Organogenesis stock.